In vitro prediction and in vivo verification of enantioselective human tofisopam metabolite profiles

Drug Metabolism and Disposition

Volumn 35, Issue 10, 2007, Pages 1894-1902

  Cameron, Michael D ^a,d   Wright, Jason ^b   Black, Christopher B ^b   Ye, Naidong ^c  

^a Scripps Florida ^*  (United States)

^b CellzDirect Inc   (United States)

^c Pharmos Corporation   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIAZEPINE DERIVATIVE; DRUG METABOLITE; FURAFYLLINE; KETOCONAZOLE; MEPHENYTOIN; QUINIDINE; SULFAPHENAZOLE; TOFISOPAM;

ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; ENANTIOSELECTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; METHYLATION; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL;

ADULT; BENZODIAZEPINES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; RECOMBINANT PROTEINS; STEREOISOMERISM;

EID: 34748829368     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.015875     Document Type: Article

References (19)

1. Andrasi F, Horvath K, Sineger E, Berzsenyi P, Borsy J, Kenessey A, Tarr M, Lang T, Korosi J, and Hamori T (1987) Neuropharmacology of a new psychotropic 2,3-benzodiazepine. Arzneimittelforschung 37:1119-1124.
2. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832.
3. Brian EL (2001) An introduction to enantiomers in psychopharmacology. Hum Psychopharmacol Clin Exp 16:S79-S84.
4. Cameron MD, Wen B, Allen KE, Roberts AG, Schuman JT, Campbell AP, Kunze KL, and Nelson SD (2005) Cooperative binding of midazolam with testosterone and alpha-naphthoflavone within the CYP3A4 active site: a NMR T1 paramagnetic relaxation study. Biochemistry 44:14143-14151.
5. Elekes I, Lang T, Csanyi E, Horvath G, and Korosi J (1981) Absorption, distribution, elimination and metabolism of tofizopam, a new 2,3-benzodiazepine derivative, in animal experiments. Farmaco [Prat] 36:542-552.
6. Emoto C, Murase S, Sawada Y, Jones BC, and Iwasaki K (2003) In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metab Pharmacokinet 18:287-295.
7. [FDA] U.S. Food and Drug Administration (1992) FDA's policy statement for the development of new stereoisomeric drugs. http://www.fda.gov/cder/guidance/ stereo.htm.
8. Hickman D, Wang JP, Wang Y, and Unadkat JD (1998) Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 26:207-215.
9. Hovi-Viander M, Kanto J, Scheinin H, and Scheinin M (1985) Tofisopam and midazolam: differences in clinical effects and in changes of CSF monoamine metabolites. Br J Clin Pharmacol 20:492-496.
10. Klebovich I and Abermann M (1993) [Pharmacokinetics and metabolism of tofizopam (Grandaxin)] (Hungarian). Acta Pharm Hung 63:83-90.
11. Lasker JM, Wester MR, Aramsombatdee E, and Raucy JL (1998) Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353:16-28.
12. Masimirembwa CM, Otter C, Berg M, Jonsson M, Leidvik B, Jonsson E, Johansson T, Backman A, Edlund A, and Andersson TB (1999) Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research. Drug Metab Dispos 27:1117-1122.
13. Nedogoda SV and Parshev VV (2000) [Treatment of irritable bowel syndrome with dicetelium and spasmomen] (Russian). Klin Med (Mosk) 78:42-46.
14. Niwa T, Shiraga T, Ishii I, Kagayama A, and Takagi A (2005) Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull 28:1711-1716.
15. Pakkanen A, Kanto J, Kangas L, and Mansikka M (1980) Comparative study of the clinical effects of tofizopam, nitrazepam and placebo as oral premedication. Br J Anaesth 52:1009-1012.
16. Racha JK, Rettie AE, and Kunze KL (1998) Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochemistry 37:7407-7419.
17. Sai Y, Dai R, Yang TJ, Krausz KW, Gonzalez FJ, Gelboin HV, and Shou M (2000) Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica 30:327-343.
18. Tomori E, Elekes I, Lang T, and Horvath G (1984) Investigation of metabolites of tofizopam in man and animals. Pol J Pharmacol Pharm 36:423-430.
19. Tomori E, Horvath G, Elekes I, Lang T, and Korosi J (1982) Investigation of the metabolites of tofizopam in man and animals by gas-liquid chromatography-mass spectrometry. J Chromatogr 241:89-99.